U.S. House and Senate appropriations committees want federal healthcare officials to brief them by April “on actions taken to safeguard covered entities’ lawful access to discounted drugs” under the 340B program.
The directive to the Health Resources and Services Administration is included in the report that accompanies the $1.7 trillion fiscal year 2023 omnibus appropriations bill that Congress is expected to pass before the end of the week.
U.S. House and Senate appropriations committees want federal healthcare officials to brief them by April “on actions taken to safeguard covered entities' lawful access to discounted drugs” under the 340B program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
